Analyst Activity – Needham & Company LLC Raises Its Price Target On NASDAQ:RYTM – Rhythm Pharmaceuticals (NASDAQ:RYTM) to

Analyst Ratings For NASDAQ:RYTM – Rhythm Pharmaceuticals (NASDAQ:RYTM)

Story continues below

Today, Needham & Company LLC raised its price target on NASDAQ:RYTM – Rhythm Pharmaceuticals (NASDAQ:RYTM) to per share.

Some recent analyst ratings include

  • 11/14/2017-Cowen Reiterated Rating of Buy.
  • 10/30/2017-Morgan Stanley initiated coverage with a Equal Weight rating.
  • 10/30/2017-Bank of America initiated coverage with a Buy rating.

Recent Insider Trading Activity For NASDAQ:RYTM – Rhythm Pharmaceuticals (NASDAQ:RYTM)
NASDAQ:RYTM – Rhythm Pharmaceuticals (NASDAQ:RYTM) has insider ownership of 4.93% and institutional ownership of 88.30%.

  • On 5/21/2018 Orbimed Advisors Llc, Major Shareholder, sold 131,636 with an average share price of $30.88 per share and the total transaction amounting to $4,064,919.68.
  • On 10/10/2017 David P Meeker, Director, bought 25,000 with an average share price of $17.00 per share and the total transaction amounting to $425,000.00.
  • On 10/10/2017 James E Flynn, Insider, bought 355,000 with an average share price of $17.00 per share and the total transaction amounting to $6,035,000.00.
  • On 10/10/2017 S.A. Ipsen, Major Shareholder, bought 20,000 with an average share price of $17.00 per share and the total transaction amounting to $340,000.00.
  • On 10/5/2017 Bros. Advisors Lp Baker, Insider, bought 885,000 with an average share price of $17.00 per share and the total transaction amounting to $15,045,000.00.

Recent Trading Activity for NASDAQ:RYTM – Rhythm Pharmaceuticals (NASDAQ:RYTM)
Shares of NASDAQ:RYTM – Rhythm Pharmaceuticals closed the previous trading session at 33.20 up +0.43 1.31% with 31.90999984741211 shares trading hands.

An ad to help with our costs